Multiple Genes Discovered Are Key to Kidney Cancer
By LabMedica International staff writers Posted on 14 Jul 2014 |
A genomic analysis of clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, has uncovered 31 genes that are fundamental to the development, growth and spread of the cancer.
The ccRCC kidney cancer is one of the top 10 solid cancers in the USA, and while the prognosis for kidney cancer that has not spread is good, patients with advanced or metastatic cancer will develop drug resistance. Patients with untreated metastatic disease have a five-year overall survival rate of less than 10%.
Scientists at the Mayo Clinic (Jacksonville, FL, USA) purified ribonucleic acid (RNA) samples derived from 72 matched normal and diseased ccRCC patient tissue across all stages of the disease. They looked at over- and under-expression of RNA from the tissue, as well as protein production because genes express RNA to produce protein. They found almost 6,000 genes that fit that description. They isolated and tested 195 genes that are consistently elevated across patient samples.
Gene array expression analysis was performed using Human Genome U133 Plus 2.0 Array chips (Affymetrix; Santa Clara, CA, USA). The team also performed among other techniques real-time quantitative polymerase chain reaction analysis, immunohistochemistry and immunocytochemistry, western blot analysis, and cell-death analysis via flow cytometry. Cell death analysis was performed using an Accuri C6 flow cytometer (BD Biosciences; San Jose, CA, USA) with unstained natural T (NT) cells used to set population parameters. The investigators found eight genes had not been previously linked to kidney cancer, and six other genes that were never known to be involved in any form of cancer.
John A. Copland, PhD, a molecular biologist and the study's senior investigator, said, “The power of this study is that we looked at genes discovered to be over-expressed in patients' tumors and determined their function in kidney cancer, which has not been done on a large scale before. This is a seminal step in identifying key pathways and molecules involved in kidney cancer so that specific therapies that target these new genes can be developed to treat this cancer.” The study was published on June 12, 2014, in the journal Oncotarget.
Related Links:
Mayo Clinic
Affymetrix
BD Biosciences
The ccRCC kidney cancer is one of the top 10 solid cancers in the USA, and while the prognosis for kidney cancer that has not spread is good, patients with advanced or metastatic cancer will develop drug resistance. Patients with untreated metastatic disease have a five-year overall survival rate of less than 10%.
Scientists at the Mayo Clinic (Jacksonville, FL, USA) purified ribonucleic acid (RNA) samples derived from 72 matched normal and diseased ccRCC patient tissue across all stages of the disease. They looked at over- and under-expression of RNA from the tissue, as well as protein production because genes express RNA to produce protein. They found almost 6,000 genes that fit that description. They isolated and tested 195 genes that are consistently elevated across patient samples.
Gene array expression analysis was performed using Human Genome U133 Plus 2.0 Array chips (Affymetrix; Santa Clara, CA, USA). The team also performed among other techniques real-time quantitative polymerase chain reaction analysis, immunohistochemistry and immunocytochemistry, western blot analysis, and cell-death analysis via flow cytometry. Cell death analysis was performed using an Accuri C6 flow cytometer (BD Biosciences; San Jose, CA, USA) with unstained natural T (NT) cells used to set population parameters. The investigators found eight genes had not been previously linked to kidney cancer, and six other genes that were never known to be involved in any form of cancer.
John A. Copland, PhD, a molecular biologist and the study's senior investigator, said, “The power of this study is that we looked at genes discovered to be over-expressed in patients' tumors and determined their function in kidney cancer, which has not been done on a large scale before. This is a seminal step in identifying key pathways and molecules involved in kidney cancer so that specific therapies that target these new genes can be developed to treat this cancer.” The study was published on June 12, 2014, in the journal Oncotarget.
Related Links:
Mayo Clinic
Affymetrix
BD Biosciences
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Molecular Diagnostics News
- Game-Changing Blood Test for Stroke Detection Could Bring Life-Saving Care to Patients
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays